ABVD is a chemotherapy regimen used primarily to treat Hodgkin lymphoma, consisting of four drugs: doxorubicin, bleomycin, vinblastine, and dacarbazine. This combination is significant in clinical practice due to its effectiveness in achieving remission and improving survival rates in patients with this malignancy. A key association is the risk of pulmonary toxicity, particularly from bleomycin, which necessitates careful monitoring of lung function during treatment.
Please confirm you want to block this member.
You will no longer be able to:
Please allow a few minutes for this process to complete.